ライフサイエンスコーパス: tumor volume

1 analyzed for SUV(max), SUV(mean), and total tumor volume.

2 widespread intratumoral necrosis and reduced tumor volume.

3 al histopathological analysis underestimates tumor volume.

4 nse to anti-VEGF treatment, the reduction in tumor volume.

5 ction in fBV in the absence of any change in tumor volume.

6 -500 mmol/L and injection volumes 20%-80% of tumor volume.

7 es were a positive, linear function of total tumor volume.

8 Both formulas tended to overestimate the tumor volume.

9 mages and caliper were used to determine the tumor volume.

10 ere generated from pixel ADCs from the whole tumor volume.

11 en if these cells comprise a minority of the tumor volume.

12 itinib monotherapy was tested for effects on tumor volume.

13 on of PSMA PET biomarkers such as whole-body tumor volume.

14 act that (18)F-FDG uptake is proportional to tumor volume.

15 tumors, is also in this cohort a measure of tumor volume.

16 received 21.6 Gy to the preoperative primary tumor volume.

17 Cancer survival is related to tumor volume.

18 tumor tracer input) in patients with higher tumor volumes.

19 3 patients demonstrated a reduction in uveal tumor volumes.

20 iregional (contrast-enhanced and unenhanced) tumor volumes.

21 CT scans were segmented to derive liver and tumor volumes.

22 ; P < .0001), rendered the smallest relative tumor volume (0.65 mm(3) +/- 0.15, P < .0001) and relati

23 ; P < .0001), rendered the smallest relative tumor volume (0.65 mm(3) +/- 0.15, P < .0001) and relati

24 xenografts, as well as the smallest relative tumor volume (0.68 mm(3) +/- 0.13, P < .05) and relative

25 xenografts, as well as the smallest relative tumor volume (0.68 mm(3) +/- 0.13, P < .05) and relative

26 Mean HCC tumor volumes 10 days after therapy were 1.68 cm(3) +/-

27 blished clinical imaging biomarker of active tumor volume ([(18)F]FET) in conjunction with MRI.

28 A greater decrease in lung tumor volume (-37.2% vs. -27.6%) was associated with a b

29 breast tumor model based on measurements of tumor volume, 4T1-luc breast tumor bioluminescence, and

30 .0005), resulting in a striking reduction in tumor volume (50% smaller) 2 months following treatment.

31 mage analysis and total (68)Ga-DOTATATE-Avid tumor volume ((68)Ga-DOTATATE TV) was determined.

32 5% CI: 6%, 65%) and a 127% increase in total tumor volume (95% CI: 12%, 358%).

33 e above an SUVmax of 10 (TLF10) and fluoride tumor volume above an SUVmax of 10 (FTV10).

34 All patients received IGRT to reduced tumor volumes according to strict protocol guidelines.

35 Baseline lung tumor volume addressed with (68)Ga-DOTA-E-[c(RGDfK)](2)

36 te-specific membrane antigen (PSMA)-positive tumor volume after radioligand therapy (RLT) based on a

37 odeling methods to predict the PSMA-positive tumor volume after RLT.

38 The tumor volume after therapy was predicted on the basis of

39 erobserver agreement was excellent for whole-tumor volume analysis (range, 0.91-0.95) but was only mo

40 fficient (ADC) parameters were determined by tumor volume analysis.

41 xenograft tumors revealed a 25% reduction in tumor volume and 12% increase in survival with metalloin

42 a CDK7 inhibitor showed marked reduction in tumor volume and absence of regrowth in the xenograft mo

43 of cSCC cells in vitro and reduced xenograft tumor volume and angiogenesis in vivo.

44 gents used in MRI are distributed within the tumor volume and can act as neutron capture agents.

45 sizes from experiments assessing changes in tumor volume and conducted subgroup analyses based on pr

46 , multivariate analysis identified metabolic tumor volume and derived neutrophil-to-lymphocyte ratio

47 a preclinical model of PDAC reduces primary tumor volume and eliminates metastatic disease.

48 C PDX models showed significant reduction in tumor volume and enhanced delay in tumor regrowth follow

49 poxia; nor did we see an association between tumor volume and hypoxia.

50 ncement serves as an imperfect surrogate for tumor volume and is influenced by agents that affect vas

51 containing 5mg of 5-ALA did not suppress the tumor volume and led to tumor growth comparable to the u

52 Unexpectedly, primary tumor volume and liver metastases were increased in 5-LO

53 raits and 2 conventional features (metabolic tumor volume and maximum SUV).

54 molecules is frequently heterogeneous in the tumor volume and may be driven by hypoxia and HIF-1alpha

55 There was an inverse correlation between tumor volume and mean dose to the parotids (r = -0.41) a

56 on of detection, quantitative measurement of tumor volume and quantitative follow-up of the tumor dev

57 d median values were obtained by using whole-tumor volume and single-section ROI analyses.

58 rmance of IVIM parameters derived from whole-tumor volume and single-section ROIs for prediction of h

59 d, and tumor burden was analyzed using total tumor volume and total lesion activity.

60 quantification metrics, including metabolic tumor volume and total lesion glycolysis (TLG) with diff

61 uptake measures such as metabolically active tumor volume and total lesion glycolysis (TLG).

62 After adjustment of the results on tumor volume and tumor location, the volume of lens rece

63 In participants with glioma, the tumor volume and tumor subcompartments were compared wit

64 No significant difference in tumor volume and TVR was found among the six MR imaging

65 nitiating capacity of TNBC cells and reduced tumor volume and viability when administered simultaneou

66 rom dose maps were correlated with change in tumor volume and volumetric RECIST response using linear

67 ated mice correlated with subsequent reduced tumor volume and was a predictive biomarker of response.

68 Furthermore, APIO-EE-07 decreased tumor volume and weight in human patient-derived xenogra

69 agreement between PET- and histology-derived tumor volumes and intra- and interobserver agreement of

70 XP3 expression was associated with increased tumor volumes and poor prognosis in PDAC especially comb

71 using histogram analysis derived from whole-tumor volumes and single-section regions of interest (RO

72 mall cell lung cancer, but in the esophageal tumors, volume and heterogeneity had less complementary

73 or metabolism and volume (SUVmean, metabolic tumor volume) and increase in healthy splenic metabolism

74 tal tumor volume (TTV) (sum of PSMA-positive tumor volumes) and total tumor burden (TTB) (sum of all

75 ing tumor volume (ETV [cm(3)] and % of total tumor volume), and total and enhancing tumor burden (%),

76 ed as xenografts in mice similarly decreased tumor volume, and expression of a lentivirus blocking NG

77 0.89, 0.82, and 0.93 for mean ADC, baseline tumor volume, and follow-up tumor volume, respectively.

78 or receptor type 2 (VEGFR2) phosphorylation, tumor volume, and histopathologic changes.

79 tumor-to-background ratio, total functional tumor volume, and mean and minimum ADC were measured on

80 quality, imager magnet and sequence, average tumor volume, and reader variability in tumor volume on

81 SUVmax, SUVmean, metabolic tumor volume, and total lesion avidity were obtained for

82 The SUVmax, SUVmean, metabolic tumor volume, and total lesion avidity were obtained for

83 lic parameters including SUV(max), metabolic tumor volume, and total lesion glycolysis (TLG) were det

84 cluding tumor SUV(max), SUV(mean), metabolic tumor volume, and total lesion glycolysis, as well as pe

85 SUVmean, SUVpeak, TLG, metabolically active tumor volume, and tumor-to-blood and -liver ratios were

86 tes, kidney somatostatin receptor densities, tumor volumes, and release rates was investigated.

87 SUVmean; size-incorporated SUVmax; metabolic tumor volume; and total lesion glycolysis.

88 ak), and SUV(max) normalized to body weight; tumor volume; and total lesion uptake (TLU).

89 Conclusion Bevacizumab treatment decreased tumor volumes, angiogenesis, and oxygenation, thereby re

90 group exhibited a significantly lower final tumor volume (ANOVA, p = 0.008) and growth rate than con

91 l response trends for logarithmically scaled tumor volume are estimated as regression splines in a ge

92 livered via external-beam radiotherapy using tumor volume as a measure of response.

93 e semiautomated quantification of whole-body tumor volume as a PSMA PET biomarker is an unmet clinica

94 ible with a median of only 57% change in the tumor volume as compared to a median of 174% change of v

95 e T2 signal in >=90% versus <90% of baseline tumor volume (as defined by the "test" radiologist; haza

96 Brain tumor volume assessment is a major challenge.

97 Compared with controls, median relative tumor volume at day 23 after injection was reduced by 55

98 ith tumor metabolism, but not with metabolic tumor volume at regional or distant levels, suggests tha

99 We did not observe a difference in tumor volume at the start of the treatment, nor in HER2

100 oncentrations, planar scintigraphy data, and tumor volumes before and after (6 wk) therapy.

101 fference compared to vehicle control despite tumor volume being reduced to levels similar to those re

102 Concordance for metabolic tumor volume between (18)F-fluciclovine and (18)F-FDG wa

103 or-to-brain-ratio [TBRmax/TBRmean], biologic tumor volume [BTV], and time-activity curves with minima

104 combined, it increased the apparent overall tumor volume by 30%; however, volumes remained small (me

105 th only 1 mouse reaching 5 times the initial tumor volume by 60 d after treatment, compared with a me

106 established murine and human STSs decreased tumor volume by almost two-thirds and cell proliferation

107 .ResultsThere was a 37%-75% reduction in HCC tumor volume by day 7 after ablation in the BEZ235 plus

108 Estimation of tumor volume by PET of noninfiltrating brain tumors was

109 t changes in pathophysiology associated with tumor volume can selectively change tumor uptake of nano

110 ient responses, increasing the difference in tumor volume change between the two patients by > 40%.

111 en gene expression levels and post-treatment tumor volume changes in PDX models.

112 Tumor volume changes measured by magnetic resonance imag

113 The percent tumor volume characterized by hyperintense T2 signal is

114 Total tumor volume (cm(3)) and enhancing tumor volume (ETV [cm

115 group showed 5.49 and 3.25 fold reduction in tumor volume compared to Nos and DTX alone groups, respe

116 g adenocarcinoma cells resulted in decreased tumor volume compared to vehicle control; however, while

117 nib resulted in confirmed partial responses (tumor volume decreases from baseline of >/=20%) in 17 of

118 Tumor volume delineations were quite repeatable, with an

119 ncentration and magnitude of the decrease in tumor volume did not differ between oligodendrogliomas t

120 ding SUV, proliferative volume, or metabolic tumor volume, did not correlate with outcome.

121 CAR T cells led to significant regression in tumor volume due to enhanced CAR TIL infiltrate, decreas

122 The therapy study showed a decrease in mean tumor volume during the first 2 wk for both the (177)Lu-

123 nships between study design and experimental tumor volume effect sizes.

124 In contrast, tumor volume estimation by PET of infiltrating brain tum

125 Total tumor volume (cm(3)) and enhancing tumor volume (ETV [cm(3)] and % of total tumor volume),

126 dol deposition was correlated with enhancing tumor volume (ETV) on baseline and follow-up MRI.

127 Mice were sacrificed when tumor volume exceeded 1,500 mm(3) Results: (225)Ac-RPS-0

128 stable disease or better, and had decreased tumor volume following treatment.

129 sulted in 84% accuracy when using the entire tumor volume for feature extraction and 74% accuracy for

130 implications of PSMA PET-derived whole-body tumor volume for overall survival are poorly elucidated

131 ng metrics, including midtreatment metabolic tumor volume for predicting PFS, with a C-index of 0.72

132 tive deviation of the predicted and measured tumor volume for PSMA-positive tumor cells (6 wk after t

133 The average tumor volumes for (18)F-FET uptake and increased Cho/NAA

134 ant treatment for 28 d significantly reduced tumor volumes for WT-ER but only stabilized volumes for

135 ctice that allowed a significant increase in tumor volumes from baseline before detection.

136 established predictors, including functional tumor volume (FTV) and histopathologic and demographic f

137 Functional tumor volume (FTV), computed from MR images by using enh

138 haracteristics (longest diameter, functional tumor volume [FTV], peak percentage enhancement [PE], pe

139 ition of ATR and GLUT1 significantly reduced tumor volume gain in an autochthonous mouse model of Kra

140 ed to summarize between-group differences in tumor volume growth with statistical measures of uncerta

141 N = 90) were found in- and outside the gross tumor volume (GTV) in 33.3% and 8.9%, and only microscop

142 tio (TMR(max)) at 4 h after injection, gross tumor volume (GTV), relative hypoxic volume based on M (

143 y with maximum standardized uptake value and tumor volume (hazard ratio, 1.5 and 2.0, respectively; P

144 5; P = 0.024), whereas a (68)Ga-DOTATOC-avid tumor volume higher than 578 cm(3) (75th percentile) was

145 5; P = 0.024), whereas a (68)Ga-DOTATOC-avid tumor volume higher than 578 ml (P75) was associated wit

146 (18)F-FDG PET measurement of tumor volume holds promise but is not yet a clinical too

147 d ratio [HR], 1.22; 95%CI, 0.98-1.53], liver tumor volume (HR, 1.002; 95%CI, 1.0004-1.003), subsequen

148 ween the two reviewers regarding MRI-derived tumor volume (ICC, 0.979).

149 ctive Data Language was developed to measure tumor volume in (18)F-FDG PET images.

150 In vivo, AUY922 showed decrease in tumor volume in 36.4% of rats (control = 9.4%), increase

151 e basis of tumour incidence, body weight and tumor volume in DMBA-induced rats.

152 d decreases neovasculature in HUVEC and also tumor volume in EAT mouse models.

153 in accelerated graft rejection and decreased tumor volume in mouse models.

154 In this study, we measured tumor volume in patients with malignant pleural mesothel

155 of (68)Ga-DOTATATE PET/CT-based analysis of tumor volume in patients with NETs.

156 ple, fast, and accurate method of estimating tumor volumes in the clinical setting, suggesting that t

157 Disease progression (tumor volume increase from baseline of >/=20%) has not b

158 roup, with a corresponding reduction in mean tumor volume, increase in the CD8 T-cell population, and

159 Mean MRI tumor volume increased by 109.2% in controls (n = 32) an

160 llulose-ethanol injections of one-fourth the tumor volume induced complete regression in 100% of tumo

161 tions of either four times or one-fourth the tumor volume induced complete regression of 33% and 0% o

162 Brain tissue was analyzed for tumor volume, invasiveness, hypoxia, vascular density, p

163 Total tumor volume is a good predictor of successful downstagi

164 Tumor volume is a parameter used to evaluate the perform

165 uation of therapeutic response by changes in tumor volume is misleading, as volume changes reflect th

166 Median time to tumor progression (tumor volume larger than at day 0) was 3 d for controls,

167 ids, is significantly enriched only in small tumors (volume < 5.7 cm (3)).

168 We assessed the accuracy of semi-automated tumor volume maps of plexiform neurofibroma (PN) generat

169 images, such as SUVmax, metabolically active tumor volume (MATV), total lesion glycolysis, and, more

170 n and dependence on the metabolically active tumor volume (MATV), which has already been shown to be

171 Therapeutic efficacy was assessed by tumor volume measurements (CT), time to progression (TTP

172 Therapeutic efficacy was monitored by tumor volume measurements and overall survival.

173 by the World Health Organization (WHO) with tumor volume measurements as the standard of reference a

174 apeutic efficacy of PSMA RLT was assessed by tumor volume measurements, time to progression, and surv

175 ted that the parameters metabolically active tumor volume (MTV) and total lesion glycolysis (TLG) are

176 is pilot study was to determine if metabolic tumor volume (MTV) and total lesion glycolysis (TLG) cou

177 t-order radiomic features, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), ar

178 tomography (PET-CT) scans, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), wo

179 Metabolic tumor volume (MTV) and total lesion glycolysis were meas

180 ility of these metrics, as well as metabolic tumor volume (MTV) and total uptake of choline in the le

181 Recently, total metabolic tumor volume (MTV) and tumor lesion glycolysis have emer

182 ether combining them with baseline metabolic tumor volume (MTV) could improve prediction of progressi

183 Metabolic tumor volume (MTV) is a promising biomarker of pretreatm

184 In the PET images, the metabolically active tumor volume (MTV) of the primary tumor was delineated w

185 6668/RTOG 0235, high pretreatment metabolic tumor volume (MTV) on (18)F-FDG PET was found to be a po

186 max and SUVmean, respectively) and metabolic tumor volume (MTV) with a threshold of 40%, 50%, and 60%

187 e, mean standardized uptake value, metabolic tumor volume (MTV), and IMH index of the primary tumor i

188 lesion-to-background ratio (LBR), metabolic tumor volume (MTV), and lesion diameter in up to 5 (18)F

189 tandardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) wa

190 SUVmean, respectively) for tumor, metabolic tumor volume (MTV), and total lesion glycolysis (TLG).

191 We obtained (18)F-FET metabolic tumor volumes (MTVs) as well as mean and maximum tumor-t

192 s of avidity and volume (including metabolic tumor volume), nodal SUVmax, and our new concepts of mN

193 Contrast-enhanced tumor volume, noncontrast-enhanced T2 fluid-attenuated i

194 nt predictive agreement with the decrease in tumor volumes observed in TCZ-treated mice, as well as a

195 rbed dose was associated with a reduction in tumor volume of 1.8%, 1.8%, and 1.5%, respectively, and

196 0.9 years; range, 3.0 to 18.5) with a median tumor volume of 1205 ml (range, 29 to 8744) received sel

197 Tumor volume of 37 cm(3) or greater (hazard ratio [HR],

198 of NMIIA or NMIIB lowers the growth rate and tumor volume of 3MC-induced tumor in vivo.

199 ly diminished cell-cycle gene expression and tumor volume of A431-derived xenograft tumors.

200 down regulated with apoptosis in ~27% of the tumor volume of doxorubicin-resistant human HCC after a

201 mputed tomography (micro-CT) to estimate the tumor volume of ex vivo tumor-burdened lungs.

202 Tumors were segmented to produce whole-tumor volumes of interest (VOI(WT)) and 40% isocontours

203 After 25 days, the final tumor volumes of the mice varied from 12 mm(3) to 62 mm(

204 rage tumor volume, and reader variability in tumor volume on IRV was studied by using intraclass corr

205 >/= 7) or who have significant increases in tumor volume on subsequent biopsies should be offered ac

206 hough there was no significant difference in tumor volume on the day of imaging, in the high-uptake g

207 ere compared with the standard of reference (tumor volume) on the basis of RECIST, COG, and WHO thera

208 years, or upgrading (defined as increase in tumor volume or grade) on follow-up prostate biopsy.

209 influenced by age and cannot be predicted by tumor volume or Koos grading alone.

210 that the (18)F-FDG PET/CT-derived metabolic tumor volume or total lesion glycolysis, acquired after

211 on of tumor growth resulted in a decrease in tumor volume over a subsequent course of 4 weeks.

212 xponential growth are useful for summarizing tumor volume over ranges for which the growth model hold

213 Overall, relative tumor volume over time differed across treatment groups

214 th topoisomerase II inhibitor, and change in tumor volume over time was documented.

215 ipheral NK cell concentrations or changes in tumor volume over time.

216 In multivariate analysis, the tumor volume (P < .01) and an equatorial tumor location

217 Treated rats had reduced tumor volume (p < 0.01), reduced proliferation (Ki-67 st

218 significantly greater reduction in metabolic tumor volume (P = 0.03) and total lesion glycolysis (P =

219 with xenograft tumors significantly reduced tumor volumes (P < .001).

220 get lesions (PERCIST(SULpeak)) and metabolic tumor volume PERCIST (PERCIST(MTV)) were applied separat

221 published in vivo measurements of xenograft tumor volume, producing a model that accurately predicts

222 The whole-body tumor volume (PSMA(TV50)), SUV(max), SUV(mean), and othe

223 Volumetric parameters, that is, PSMA-derived tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA),

224 are computed, that is, PSMA ligand-positive tumor volume (PSMA-TV), PSMA ligand-positive total lesio

225 he LAC/PYR was significantly correlated with tumor volume (R = 0.903, P = 0.005) and MCT 1 (R = 0.85,

226 Although tumor volumes ranged over 3 orders of magnitude, SUL(ave

227 with manual tracing of each section, and the tumor volume ratio (TVR) was calculated.

228 Total tumor volume reduced in all men by 74.5% (IQR, 27-97) (P

229 maging outcomes consisted of six responders (tumor volume reduction >90%) and five partial responders

230 lar hemangioblastoma, octreotide resulted in tumor volume reduction, symptom stabilization, and tumor

231 tion of the compound in the tumor led to 30% tumor volume reduction, which represents the first demon

232 ed mice were imaged prior to therapy-induced tumor volume reduction.

233 ound to correlate well with subject-specific tumor volume reduction.

234 be formed that correlated exponentially with tumor volume reduction.

235 rkers of cell death and preceded decrease in tumor volume, reflected reduced flux from glucose to lac

236 sive tumors that occurred earlier than gross tumor volume regression.

237 itored triweekly by caliper measurement, and tumor volume relative to baseline was calculated.

238 an ADC, baseline tumor volume, and follow-up tumor volume, respectively.

239 searched for all animal experiments testing tumor volume response to sorafenib monotherapy in any ca

240 relation analysis between [Pi], pO2, pHe and tumor volumes reveal an association of high [Pi] with ch

241 ts independently estimated the percentage of tumor volume showing hyperintense T2 signal at baseline.

242 tology, T stage, quantitative clinical stage/tumor volume staging, adjuvant chemotherapy, intraoperat

243 marizing longitudinally measured preclinical tumor volume studies to encompass studies with nonlinear

244 on of the device to the mouse model confirms tumor volume suppression and improved survival rate.

245 ackground ratios (TBR), the total functional tumor volume (TFTV), ADCmean and ADCmin were measured ba

246 ET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refrac

247 the prognostic impact of the total metabolic tumor volume (TMTV) measured at baseline with [(18)F]flu

248 prognostic value of baseline total metabolic tumor volume (TMTV) measured on (18)F-FDG PET/CT with ad

249 dies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL

250 Total metabolic tumor volume (TMTV), calculated from (18)F-FDG PET/CT ba

251 dized uptake value [SUVmax], total metabolic tumor volume [TMTV]).

252 ng the influence of baseline total metabolic tumor volume (TMTV0) on rituximab PK and of TMTV0 and ri

253 Here, we varied tumor volume to determine whether cancer pathophysiology

254 ivalent tumor SUV(max), SUV(mean,) and total tumor volume, total lesion activity was significantly hi

255 rsister populations can explain the observed tumor volume trajectories and yields an estimated preexi

256 We applied the model to 20 tumor volume trajectories of EGFR-mutant lung cancer pat

257 Additionally, patient-based total tumor volume (TTV) (sum of PSMA-positive tumor volumes)

258 ables, tumor characteristics including total tumor volume (TTV) and up-to-7 criteria were recorded.

259 s according to the previously proposed total tumor volume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP

260 o-actual dose ratio ([Formula: see text]) in tumor volumes (TVs) and nontumor volumes (NTVs) for glas

261 The accurate tumor volume values provided by these formulas may help

262 n, median, and D(70) (minimum dose to 70% of tumor volume) values determined from dose maps were corr

263 sLT(2)R antagonist significantly reduced LLC tumor volume, vessel density, dextran leakage, and metas

264 information with histogram quantification of tumor volumes, volume ratios, apparent diffusion coeffic

265 Mean tumor volume was 1.8 ml (range 0.1-18.5).

266 By PET, the mean U87MG tumor volume was 35.0 mm3 using 18F-FDG and 34.1 mm3 wit

267 COVA was applied to gauge how well the total tumor volume was a predictor for the ADC and (18)F-FDG,

268 Following optimization, a 90% reduction in tumor volume was achieved 2 weeks after the beginning of

269 Total tumor volume was an independent predictor of successful

270 In drug-resistant xenografts, tumor volume was decreased 2.33 and 1.41 fold in xenogra

271 The MRI-derived tumor volume was estimated.

272 Tumor volume was measured to follow the treatment effect

273 Increased tumor volume was overall associated with reduced surviva

274 Mean tumor volume was significantly greater in the MW (95.3 m

275 Variability in reader-derived tumor volume was significantly related to IRV for all pa

276 and SU5416 decreased tumor vascular density, tumor volume was unaffected.

277 n the MSLT-II screening phase population, SN tumor volume was usually too small to be reliably detect

278 ent between PET- and histology-derived U87MG tumor volumes was achieved with 11C-MeAIB, MAP3D reconst

279 quantification of the overall and enhancing tumor volumes was performed in each patient.

280 , the time to reach twice the preirradiation tumor volume, was defined as the endpoint.

281 alue of baseline whole-body metabolic active tumor volume (WB-MATV) and total lesion glycolysis (WB-T

282 Baseline whole-body metabolically active tumor volume (WB-MATV) measured by (18)F-FDG PET/CT and

283 SED showed ~30-59% tumor volume/weight reduction in H1650 tumor model compa

284 l, RECIST partial response, and reduction in tumor volume were confirmed to be independently associat

285 ers and patients with a higher baseline lung tumor volume were more likely to have a higher progressi

286 alue, total lesion glycolysis, and metabolic tumor volume were used.

287 Corresponding T87 tumor volumes were 122.1 mm3 using 18F-FDG, 118.3 mm3 wi

288 Tumor volumes were compared for drug or ablation groups

289 Gross tumor volumes were defined on T2-weighted MR images, and

290 Tumor volumes were delineated manually, and the input fu

291 se in large tumors), parallels the growth in tumor volume, whereas pulmonary artery perfusion remaine

292 trolling mouse melanoma (8-fold reduction in tumor volume), which is associated with increased immune

293 The increase in total tumor volume with (11)C-methionine PET was relatively li

294 The percentage of baseline tumor volume with hyperintense T2 signal defined by a va

295 in-expressing xenografts exhibited decreased tumor volume with increased mitofusin, markers of cell c

296 ubthresholding of these contours to give the tumor volume with standardized uptake value >/=2.5.

297 of the maximum standardized uptake value and tumor volume, with concordance indexes of 0.67 and 0.64,

298 on results in a significant reduction of the tumor volume without evident side effects.

299 Such large increases in tumor volume would not be permitted in a prospective des

300 (three-ROIs), single-section (SS), and whole-tumor volume (WTV) methods in 62 patients with locally a